ARTICLE SUMMARY:
As the use of orthobiologics in orthopedic surgery booms, the FDA and leading surgeons are concerned about the lack of good clinical trial data to support their widespread use for some of the most common musculoskeletal diseases. Surgeons are tackling the problem by building a consensus around good clinical trial design, terminology, and best practices in medicine. Vericel is one of a few companies to achieve success in this field based on high-quality clinical evidence.
The orthobiologics world is gearing up for changes, both controversial and exciting.
